This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Insider Trading Alert - DVA, TMH, B, AFOP And WST Traded By Insiders

West Pharmaceutical Services (WST) - FREE Research Report

Anderson Michael A who is Vice President & Treasurer at West Pharmaceutical Services sold 9,200 shares at $46.80 on Nov. 8, 2013. Following this transaction, the Vice President & Treasurer owned 73,406 shares meaning that the stake was reduced by 11.14% with the 9,200 share transaction.

Malone Daniel who is Vice President & Controller at West Pharmaceutical Services sold 3,718 shares at $46.57 on Nov. 8, 2013. Following this transaction, the Vice President & Controller owned 8 shares meaning that the stake was reduced by 99.79% with the 3,718 share transaction.

The shares most recently traded at $46.71, up $0.14, or 0.3% since the insider transaction. Historical insider transactions for West Pharmaceutical Services go as follows:

  • 4-Week # shares sold: 6,000
  • 12-Week # shares sold: 17,883
  • 24-Week # shares sold: 20,883

The average volume for West Pharmaceutical Services has been 251,200 shares per day over the past 30 days. West Pharmaceutical Services has a market cap of $3.2 billion and is part of the health care sector and health services industry. Shares are up 67.67% year to date as of the close of trading on Friday.

West Pharmaceutical Services, Inc. manufactures and sells components and systems for injectable drug delivery and plastic packaging, as well as delivery system components for the pharmaceutical, healthcare, and consumer products industries. The stock currently has a dividend yield of 0.87%. The company has a P/E ratio of 29.6. Currently there is 1 analyst that rates West Pharmaceutical Services a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on WST - FREE

TheStreet Quant Ratings rates West Pharmaceutical Services as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, impressive record of earnings per share growth, compelling growth in net income, expanding profit margins and solid stock price performance. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full West Pharmaceutical Services Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Data for this article provided by Zacks Investment Research
5 of 5

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs